Krystal Biotech, Inc.
KRYS
$183.92
$1.170.64%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 473.02% | 2,722.79% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 473.02% | 2,722.79% | -- | -- | -- |
| Cost of Revenue | 548.38% | 7,964.13% | -- | -- | -- |
| Gross Profit | 468.12% | 2,582.53% | -- | -- | -- |
| SG&A Expenses | 15.53% | 9.35% | 8.39% | 16.51% | 24.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.63% | 22.60% | 15.10% | 14.74% | 21.95% |
| Operating Income | 206.14% | 147.95% | 102.86% | 58.15% | 19.84% |
| Income Before Tax | 639.37% | 292.55% | 177.19% | 143.70% | 109.21% |
| Income Tax Expenses | 215.37% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 715.58% | 275.67% | 175.45% | 142.25% | 107.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 715.58% | 275.67% | 175.45% | 142.25% | 107.81% |
| EBIT | 206.14% | 147.95% | 102.86% | 58.15% | 19.84% |
| EBITDA | 213.23% | 151.80% | 105.51% | 59.44% | 20.40% |
| EPS Basic | 1,619.49% | 233.16% | 169.46% | 137.44% | 103.28% |
| Normalized Basic EPS | 263.83% | 174.36% | 123.54% | 77.53% | 37.83% |
| EPS Diluted | 3,746.21% | 220.14% | 167.17% | 135.39% | 101.41% |
| Normalized Diluted EPS | 258.35% | 172.05% | 122.74% | 77.43% | 38.08% |
| Average Basic Shares Outstanding | 5.33% | 7.24% | 9.10% | 8.39% | 6.49% |
| Average Diluted Shares Outstanding | 7.84% | 10.01% | 12.51% | 10.82% | 7.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
